NaPro BioTherapeutics to Present at The Wall Street Analyst Forum On November 10
07 Novembre 2003 - 4:23PM
PR Newswire (US)
NaPro BioTherapeutics to Present at The Wall Street Analyst Forum
On November 10 BOULDER, Colo., Nov. 7 /PRNewswire-FirstCall/ --
NaPro BioTherapeutics, Inc. will present at The Wall Street Analyst
Forum analyst conference to be held in New York City November 10 -
11, 2003. Gordon Link, Senior Vice President and CFO and L. Robert
Cohen, Vice President, Investor Relations will present at 11:00
a.m. Eastern Time on Monday, November 10, 2003. The Wall Street
Analyst Forum will provide a live webcast of the audio presentation
along with accompanying presentation slides. Interested parties may
tune in to the live presentation by visiting the Company's website,
http://www.naprobio.com/. A replay of the webcast will be available
for 30 days. About NaPro BioTherapeutics NaPro BioTherapeutics,
Inc., is a life science company focused on the development of
targeted therapies for the treatment of cancer and hereditary
disease. Forward Looking Statements The statements in the webcast
presentation that are not historical facts are forward-looking
statements that represent management's beliefs and assumptions as
of the date of this webcast presentation, based on currently
available information. Forward-looking statements can be identified
by the use of words such as "believes," "intends," "estimates,"
"may," "will," "should," "anticipated," "expected" or comparable
terminology or by discussions of strategy. Although the Company
believes that the expectations reflected in such forward-looking
statements are reasonable, it cannot assure that these expectations
will prove to be correct. Such statements involve risks and
uncertainties including: risks associated with development of the
genomics, gene editing and targeted businesses, including
competition from companies in similar businesses, limitations on
the ability to market products because of the intellectual property
rights of third parties, the ability to obtain, maintain and
enforce patents; the risk that the transaction announced with
Faulding Pharmaceutical Co. may not close because it is not
approved by stockholders or otherwise or may be materially delayed;
the costs of continuing development of any or all of the Company's
development programs; the timing of when those programs will enter
the clinic; the successful commercialization of the Company's
platform technologies; the fact that the Company's business will
require substantial additional investment that the Company has not
secured; and the risk that the cash proceeds from the Faulding
transaction, if realized, will not be sufficient to fund the
Company's strategic plans for the initial development new
proprietary therapeutic candidates; and all of those factors
identified under the captions "Risk Factors," "Special Note
Regarding Forward Looking Statements" or "Cautionary Note Regarding
Forward Looking Statements" in the Company's documents filed from
time to time with the SEC, including the Company's registration
statement on Form S-3, as amended, dated August 8, 2003, its Annual
Report on Forms 10-K and 10-K/A for the year ending December 31,
2002 filed with the SEC on March 27, April 30, August 8 and October
24, 2003, and its Quarterly Report on Form 10-Q for the quarter
ended July 2, 2003 filed with the Securities and Exchange
Commission on August 8, 2003. Should one or more of these risks
materialize (or the consequences of such a development worsen), or
should the underlying assumptions prove incorrect, actual results
could differ materially from those forecasted or expected. The
Company disclaims any intention or obligation to update publicly or
revise such statements whether as a result of new information,
future events or otherwise. Additional Information In connection
with the proposed sale of assets to Faulding, NaPro has filed a
preliminary proxy statement with the Securities and Exchange
Commission (SEC). Investors and security holders are urged to read
the definitive proxy statement when it becomes available as it will
contain important information about NaPro, the proposed transaction
and related matters. Investors and security holders will have
access to free copies of the definitive proxy statement (when
available) and other documents filed with the SEC by NaPro through
the SEC website at http://www.sec.gov/ . The definitive proxy
statement and related materials may also be obtained for free (when
available) from NaPro by calling the company contact listed below.
NaPro and its directors and executive officers may be deemed to be
participants in the solicitation of proxies in connection with the
proposed transaction. Information regarding the persons who may,
under the rules of the SEC, be considered to be participants in the
solicitation of NaPro's stockholders in connection with the
proposed transaction is set forth in NaPro's proxy statement for
its 2003 annual meeting of stockholders, dated May 23, 2003 and
filed with the SEC on May 27, 2003. Additional information is set
forth in the preliminary proxy statement on file with the SEC
related to the proposed sale of assets and will be included in the
definitive proxy statement when it is filed with the SEC. For
further information please contact: L. Robert Cohen, Vice
President, Investor Relations of NaPro BioTherapeutics, Inc.,
+1-212-218-8715; or investors, Lilian Stern of Stern Investor
Relations, +1-212-362-1200, or media, Peter Steinerman of Signova,
+1-516-374-3031, both for NaPro BioTherapeutics, Inc. DATASOURCE:
NaPro BioTherapeutics, Inc. CONTACT: L. Robert Cohen, Vice
President, Investor Relations of NaPro BioTherapeutics, Inc.,
+1-212-218-8715; or investors, Lilian Stern of Stern Investor
Relations, +1-212-362-1200, or media, Peter Steinerman of Signova,
+1-516-374-3031, both for NaPro BioTherapeutics, Inc. Web site:
http://www.naprobio.com/
Copyright
Grafico Azioni Napro Biotherapeutics (NASDAQ:NPRO)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Napro Biotherapeutics (NASDAQ:NPRO)
Storico
Da Set 2023 a Set 2024